The molecular changes that lead to Fuchs’ endothelial corneal dystrophy (FECD) occur decades before the disease causes blurry vision and other noticeable symptoms in patients, new research by UT Southwestern scientists shows. This insight into this earliest stage of FECD may eventually lead to new ways of screening for and treating the common condition, which affects an estimated 4 percent of U.S. adults over the age of 40.
- Oncotarget: A novel format for recombinant antibody-interleukin-2 fusion proteins
- COVID-19 lockdown reduced mental health, sleep, exercise
- Coating implants with ‘artificial bone’ to prevent inflammation
- COVID-19 anxiety linked to body image issues
- Medical minds meet to develop novel treatment for one patient’s immune system defect